|
|
|
|
* нǹ Ű * info@kobia.kr * ϴ ȸ ҽĿ Ȯϼ * |
|
ǰǾǰó ҽ |
ڷ
|
̿Ǿǰ ȹ ũ / 2 ̿Ǿǰ 㰡‧ɻ ȸ |
̿Ǿǰ ȹ(Dynamic BIO) ũ 11 28 Ǽ( ) ֵǾ. 17 ̳̿ ϰ ̿Ǿǰ ϱ õǾ, ̿Ǿǰ 167 ߴ. ֿ 㡮17 ̳̿ ǥ а ȸ 塯 ο ̿Ǿǰ åȸ ̾, ̿Ǿǰ о οΰ ľó ο ַλ ذϴ 塯 α Ӱ Ǿ.
̳̿ : ̿Ǿǰ ϰ ȭϱ 衤а衤ľó ü å, ϰ ̿Ǿǰ о Ѵ. (̳̿ а Ұ û Click)
2017 ̳ ̿ ũ
̿Ǿǰ å Ȳ
ũ Ŀ ̿Ǿǰ 㰡ɻ ȸ(Bio- Update) ֵǾ ̿Ǿǰ 㰡ɻ ̾. ֿ 㡮17 ̿Ǿǰ 㰡ɻ ֿ Ȳ 㡯17 ̿Ǿǰ ̵ (, Ǿǰ, ġ) ̴. ǥڷ ľó Ȩ ε ̴.
ñ Ȯ
|
|
ο
ȳ |
̷ 㰡ɻ ̵ |
̷(HPV) ǰ ȿ ɻ ֽ ̷ 㰡ɻ ̵Ρ ߰ߴ.
̷(HPV, Human Papilloma Virus) : HPV ı Ű ü ϳ, HPV (ڱðξ, ξ, , ΰξ ) Ϻ, ı 縶, ȣ ȯ ϸ, ſ Ե HPV
̹ ̵ HPV ݿ ؿ ֽ Ͽ HPV ż 㰡 ǰȭ ֱ õǾ ֿ ܰ ǰ ӻ ӻ ̴.
ڷ Ȯ
̵ Ȯ |
|
˸ |
̿ùз ɻ - ̿ùз ܻ ħ |
ǰǾǰó(ó ) ǰǾǰ Ǿǰ(IPRF) ̿ùз ŷ 屹μ ̿ùз ܻ ħ() Ͽ Ǿǰ(IPRF) Ȩ ľó Ȩ Խߴ.
IPRF(International Pharmaceutical Regulators Forum) : ICH ȸ ̱, EU, Ϻ 11 籹, APEC 5 ǥ WHO 籹ڷ ȸü Ǿǰ ȯ ȣ 2008 6 ż
̹ ħ ̱, ǰ ִ ̿ùз ܻ ̵ο ó ϵ , ǰ IPRF ̿ùз ŷ ȸ ȮǾ. ֿ ̿ùз ǰ ܻ ̱, , Ϻ ̵ м 㱹 ǰ ܻ ɻ м ̴.
ܻ ) Ǿǰ ȿɡȿ Ƽ , Ǽ, ũк̰ ̿ùз Ǿǰ ӻ ǥ Ƽ ȿ Ǽ, ũк ӻ ȿɡȿ
ڷ Ȯ
ħ Ȯ |
|
Ÿ
|
Ȯ |
|
|
|
|
ӻ Ȳ |
û |
|
ǰ |
|
ܰ |
Ŭ
ġ
ڸ () |
20171129 |
༺ Ǽ ȯڸ REGN3767(-LAG-3 mAb) ܵ Ǵ REGN2810(-PD-1 mAb) , ༺, Ȱ п 1, , 뷮 ȣƮ Ȯ ü ӻ |
1 |
REGN3767
REGN2810 |
ڹݽ
ڸ
ȸ |
20171122 |
༺ Ұ Ǵ ̼ Ǵ ĵ պ (콺 ) ȯڿ 鿪 ġ ȿ ϴ Ib/II, , ٱ, , ӻ |
1/2 |
ָ,
ںƼ,
PEGPH20,
BL-8040,
۸ƾ |
ڿ
ֽȸ |
20171122 |
Kellgren & Lawrence Grade 2 ȯڸ κ(Invossa K Injection) ȿ ٱ, , ༳, , ߴ, 3 ӻ |
3 |
κ
|
ѱ
() |
20171122 |
III-IVA ұ ༺ ΰ (Locoregionally Advanced Head and Neck Squamous Cell Carcinoma, LA HNSCC) ź μ Pembrolizumab μ ǥġ Pembrolizumab ϴ III, , - ӻ |
3 |
MK-3475 |
|
|
ؿǾǰ 㰡Ȳ |
̱ |
|
|
|
Drug name |
Active Ingredients |
Submission Classification |
Company |
Approval date |
HEMLIBRA
BLA #761083 |
EMICIZUMAB |
- |
GENENTECH INC |
11/16/2017 |
PALONOSETRON
NDA #208109 |
PALONOSETRON HYDROCHLORIDE |
Ǵ |
FRESENIUS KABI USA |
11/21/2017 |
JULUCA
NDA #210192 |
DOLUTEGRAVIR;RILPIVIRINE |
ź |
VIIV HLTHCARE |
11/21/2017 |
|
|
|
|
|
|
Name |
Active Substance |
Therapeutic Area |
Date of Authorisation / Refusal |
Miglustat Gen.Orph |
miglustat |
Gaucher Disease |
10/11/2017 |
Zejula |
niraparib tosylate monohydrate |
Fallopian Tube Neoplasms
Ovarian Neoplasms
Peritoneal Neoplasms |
16/11/2017 |
|
|
ؿܹ̿Ǿǰ ӻȲ |
̱ |
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor |
Phases |
NCT03353597 |
Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects |
Aging |
Biological: Plasma Transfusion |
Chandra Duggirala
Fountain Labs, Inc. |
Phase 1
Phase 2 |
NCT03352765 |
Rituximab, Bendamustine and Melphalan Chemo-immunotherapy Followed by Reinfusion of One's Own Stem Cell for Treatment of B-cell Lymphoma in Elderly Patients |
Lymphoma |
Drug: rituximab
Drug: bendamustine
Drug: melphalan
Procedure:
Autologous Stem
Cell Transplantation (ASCT) |
Memorial Sloan Kettering Cancer Center |
Phase 1
Phase 2 |
NCT03355560 |
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy |
Head and
Neck Cancer |
Drug: Nivolumab |
Sulsau-Ul Haque
Bristol-Myers Squibb
University of Cincinnati |
Phase 2 |
NCT03355365 |
Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis |
Multiple Sclerosis |
Biological:
intrathecal MSC-NP injection
Other: lumbar puncture placebo control |
Tisch Multiple Sclerosis Research Center of New York |
Phase 2 |
NCT03354390 |
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma |
Kidney Cancer |
Biological:
cell infusion |
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health Clinical Center (CC) |
Phase 1 |
NCT03352466 |
NasoShield Study of Safety and Immunogenicity |
Healthy Volunteers |
Biological: NasoShield
Biological:BioThrax
Other: Placebo |
Altimmune, Inc. |
Phase 1 |
NCT03349983 |
Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury) |
Safety Issues |
Biological: MVA-BN-Brachyury/ FPV-Brachyury |
Bavarian Nordic |
Phase 1 |
NCT03349528 |
Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression |
Bipolar Depression |
Biological: Probiotic Supplement
Biological:
Inert Compound |
Sheppard Pratt Health System |
Phase 2 |
NCT03354728 |
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant |
Cytomegalovirus Positive
Hematopoietic Cell Transplantation Recipient |
Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Other: Laboratory Biomarker Analysis |
City of Hope Medical Center |
Phase 1
Phase 2 |
NCT03349645 |
An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee |
Severe Osteoarthritis of the Knee |
Biological: Ampion |
Ampio Pharmaceuticals. Inc. |
Phase 3 |
NCT03349710 |
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer |
Squamous Cell Carcinoma of the Head and Neck |
Biological: Nivolumab
Biological: Cetuximab
Drug: Placebo
Drug: Cisplatin |
Bristol-Myers Squibb
ONO Pharmaceutical Co. |
Phase 3 |
NCT03353675 |
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) |
NSCLC |
Biological: TG4010
Drug: Chemotherapy
Drug: Nivolumab |
Transgene
Bristol-Myers Squibb |
Phase 2 |
|
|
|
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
|
NCT03354962 |
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors |
Melanoma |
Combination Product: Nivolumab + Ipilimumab
Combination Product: Combined treatment schema |
Institut Claudius Regaud |
Phase 1
Phase 2 |
|
NCT03353831 |
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer |
Recurrent Ovarian Carcinoma |
Drug: Bevacizumab
Drug: Atezolizumab
Drug: Chemotherapy
Drug: Placebos |
AGO Research GmbH|Hoffmann-La Roche |
Phase 3 |
|
NCT03352934 |
Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy |
Cancer |
Drug: Avelumab |
Johannes Gutenberg University Mainz|Merck KGaA |
Phase 2 |
|
NCT03351361 |
Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer |
Advanced Non Small Cell Lung Cancer |
Drug: Nivolumab + Ipilimumab
Drug: Chemotherapy |
Rennes University Hospital |
Phase 3 |
|
NCT03350126 |
Interest of iRECIST Evaluation for DCR for Evaluation of Patients With Deficient MMR and /or MSI Metastatic Colorectal Cancer Treated With Nivolumab and Ipilimumab |
Metastatic Cancer Colorectal |
Drug: Ipilimumab 200 MG in 40 ML Injection
Drug: Nivolumab 10 MG/ML |
GERCOR - Multidisciplinary Oncology Cooperative Group|Bristol-Myers Squibb |
Phase 2 |
|
NCT03353675 |
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) |
NSCLC |
Biological: TG4010
Drug: Chemotherapy
Drug: Nivolumab |
Transgene
Bristol-Myers Squibb |
Phase 2 |
|
|
|
߱ |
|
|
|
NCT Number |
Title |
Conditions |
Interventions |
Sponsor/
Collaborators |
Phases |
NCT03353428 |
Intervention of Engineered Immune Effector T Cells Against Lung Cancer |
Lung Cancer|NSCLC |
Biological: LC-CTLs |
Shenzhen Geno-Immune Medical Institute |
Phase 1
Phase 2 |
NCT03351855 |
HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV |
Human Papilloma Virus |
Biological: HPV-CTLs |
Shenzhen Geno-Immune Medical Institute |
Phase 1
Phase 2 |
NCT03350633 |
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders |
Neuromyelitis
Optica Spectrum Disorders
Neuromyelitis Optica |
Drug: Tocilizumab Injection|Drug: Azathioprine |
Tianjin Medical University General Hospital |
Phase 2
Phase 3 |
NCT03355859 |
Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma |
Non Hodgkin Lymphoma |
Biological: JWCAR029 |
Zhao Weili|MingJu Therapeutics (Shanghai) Co., Ltd|Ruijin Hospital |
Phase 1 |
NCT03349255 |
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma |
Hepatocellular Carcinoma
Liver Cancer
Liver Neoplasms
Metastatic Liver Cancer |
Biological: autologous ET1402L1-CART cells |
Aeon Therapeutics (Shanghai) Co., Ltd.|Renmin Hospital of Wuhan University|Eureka Therapeutics Inc. |
Phase 1 |
|
|
ȸ ҽ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|